Cargando…
Detection of peptide-specific CTL-precursors in peripheral blood lymphocytes of cancer patients
Development of therapeutic vaccines is one of the major areas of tumour immunotherapy today. However, clinical trials of peptide-based cancer vaccines have rarely resulted in tumour regression. This failure might be due to an insufficient induction of cytotoxic T lymphocytes in the current regimes,...
Autores principales: | Maeda, Y, Hida, N, Niiya, F, Katagiri, K, Harada, M, Yamana, H, Kamura, T, Takahashi, M, Sato, Y, Todo, S, Itoh, K |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364263/ https://www.ncbi.nlm.nih.gov/pubmed/12232766 http://dx.doi.org/10.1038/sj.bjc.6600548 |
Ejemplares similares
-
A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients
por: Sato, Y, et al.
Publicado: (2004) -
Induction of viral and tumour specific CTL responses using antibody targeted HLA class I peptide complexes
por: Savage, P, et al.
Publicado: (2002) -
Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer
por: Imai, K, et al.
Publicado: (2011) -
Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles
por: Naito, M, et al.
Publicado: (2007) -
Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumour responses in vitro and in vivo
por: Gritzapis, A D, et al.
Publicado: (2005)